U.S. Court in Massachusetts Denies Teva’s Bid for Broad Production of Medicare Claims Data in FCA Action
- October 14, 2022
The government does not have to produce additional Medicare claims data sought by Teva Pharmaceuticals USA, Inc. and Teva Neuroscience, Inc. (collectively, Teva) to defend against allegations that the company illegally paid Medicare co-pays for its multiple sclerosis drug Copaxone in violation of the Anti-Kickback Statute (AKS) and False Claims Act (FCA), the U.S. District Court for the District of Massachusetts held October 11.
ARTICLE TAGS
You must be logged in to access this content.